WO1999000114A3 - Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones - Google Patents

Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones Download PDF

Info

Publication number
WO1999000114A3
WO1999000114A3 PCT/DK1998/000283 DK9800283W WO9900114A3 WO 1999000114 A3 WO1999000114 A3 WO 1999000114A3 DK 9800283 W DK9800283 W DK 9800283W WO 9900114 A3 WO9900114 A3 WO 9900114A3
Authority
WO
WIPO (PCT)
Prior art keywords
bis
ones
aromatic
prop
relates
Prior art date
Application number
PCT/DK1998/000283
Other languages
French (fr)
Other versions
WO1999000114A2 (en
Inventor
Arsalan Kharazmi
Soeren Broegger Christensen
Simon Feldbaek Nielsen
Original Assignee
Statens Seruminstitut
Arsalan Kharazmi
Soeren Broegger Christensen
Simon Feldbaek Nielsen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Statens Seruminstitut, Arsalan Kharazmi, Soeren Broegger Christensen, Simon Feldbaek Nielsen filed Critical Statens Seruminstitut
Priority to EP98929241A priority Critical patent/EP0996432A2/en
Priority to AU79080/98A priority patent/AU7908098A/en
Publication of WO1999000114A2 publication Critical patent/WO1999000114A2/en
Publication of WO1999000114A3 publication Critical patent/WO1999000114A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/01Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/40Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by doubly-bound oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • A61K31/277Nitriles; Isonitriles having a ring, e.g. verapamil
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/45Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by at least one doubly—bound oxygen atom, not being part of a —CHO group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/22Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by carbon atoms having at least two bonds to oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/32Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/36Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by carbon atoms having at least two bonds to oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/02Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C225/14Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated
    • C07C225/16Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/22Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/30Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms
    • C07C233/33Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/41Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by hydrogenolysis or reduction of carboxylic groups or functional derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C07C45/455Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation with carboxylic acids or their derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/673Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/72Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction of compounds containing >C = O groups with the same or other compounds containing >C = O groups
    • C07C45/74Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction of compounds containing >C = O groups with the same or other compounds containing >C = O groups combined with dehydration
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/80Ketones containing a keto group bound to a six-membered aromatic ring containing halogen
    • C07C49/813Ketones containing a keto group bound to a six-membered aromatic ring containing halogen polycyclic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/84Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to the use of 1,3-bis-aromatic-prop-2-en-1-ones (chalcones), 1,3-bis-aromatic-propan-1-ones (dihydrochalcones), and 1,3-bis-aromatic-prop-2-yn-1-ones for the preparation of pharmaceutical compositions for the treatment or prophylaxis of a number of serious diseases including i) conditions relating to harmful effects of inflammatory cytokines, ii) conditions involving infection by Helicobacter species, iii) conditions involving infections by viruses, iv) neoplastic disorders, and v) conditions caused by microorganisms or parasites. The invention also relates to novel chalcones and dihydrochalcones (especially alkoxy substituted variants) having advantageous substitution patterns with respect to their effect as drug substances, and methods of preparing them, as well as to pharmaceutical compositions comprising the novel chalcones. Moreover, the present invention relates to a method for the isolation of Leishmania fumarate reductase, QSAR methodologies for selecting potent compounds for the above-mentioned purposes.
PCT/DK1998/000283 1997-06-26 1998-06-26 Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones WO1999000114A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP98929241A EP0996432A2 (en) 1997-06-26 1998-06-26 Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones
AU79080/98A AU7908098A (en) 1997-06-26 1998-06-26 Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK0762/97 1997-06-26
DK76297 1997-06-26

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09462125 A-371-Of-International 1999-12-27
US10/062,208 Division US20030065039A1 (en) 1997-06-26 2002-01-31 Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones

Publications (2)

Publication Number Publication Date
WO1999000114A2 WO1999000114A2 (en) 1999-01-07
WO1999000114A3 true WO1999000114A3 (en) 1999-08-12

Family

ID=8097271

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK1998/000283 WO1999000114A2 (en) 1997-06-26 1998-06-26 Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones

Country Status (3)

Country Link
EP (1) EP0996432A2 (en)
AU (1) AU7908098A (en)
WO (1) WO1999000114A2 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0924202B1 (en) * 1997-12-16 2002-05-29 SSP Co., Ltd. Imidazole derivative and medicine comprising the same as active ingredient
JP2000256250A (en) * 1999-03-03 2000-09-19 Fuji Yakuhin:Kk Fluorinated chalcone derivative or its salt and medicine containing the same as an active ingredient
US6677350B1 (en) * 1999-09-22 2004-01-13 Advanced Life Sciences, Inc. Beta-fluoroethyl thiourea compounds and use
ES2173017B1 (en) * 1999-11-23 2004-01-16 Univ La Laguna CONTROL OF LEISHMANIASIS WITH TRANS-CHALCONA.
WO2001046110A2 (en) * 1999-12-23 2001-06-28 The University Of Georgia Research Foundation, Inc. Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states
GB0007401D0 (en) 2000-03-27 2000-05-17 Cancer Res Campaign Tech Substituted chalcones as therapeeutic compounds
ATE304367T1 (en) * 2000-06-13 2005-09-15 Univ Rutgers ANTI-CARCINOGENIC ACTIVITY OF HYDROXYLATED CHALCONIC COMPOUNDS ISOLATED FROM LICORICE ROOT
WO2001098291A2 (en) * 2000-06-20 2001-12-27 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders
FR2817749A1 (en) * 2000-12-13 2002-06-14 Aventis Pharma Sa NEW USE OF CHALCON CLASS COMPOUNDS
GB0123780D0 (en) 2001-10-03 2001-11-21 Cancer Res Ventures Ltd Substituted chalcones as therapeutic agents
GB0123777D0 (en) 2001-10-03 2001-11-21 Cancer Res Ventures Ltd Substituted chalcones as therapeutic agents
KR100567125B1 (en) 2001-11-01 2006-03-31 주식회사 안지오랩 Pharmaceutical composition for inhibiting matrix metalloproteinase activity comprising chalcone or its derivatives
KR100466168B1 (en) * 2001-11-28 2005-01-13 충남대학교산학협력단 1,3-dihydroxybenzene derivatives, a process for the preparation thereof, and a composition as a anticancer agent comprising them
PE20030758A1 (en) * 2001-12-05 2003-10-07 Aventis Pharma Sa 1,3-DIARYLPROP-2-EN-1-ONAS, COMPOSITIONS CONTAINING THEM AND THEIR USE
FR2833008B1 (en) * 2001-12-05 2004-05-21 Aventis Pharma Sa 1,3-DIARYLPROP-2-IN-1-ONES, COMPOSITIONS CONTAINING THEM, AND USE
MXPA04005864A (en) 2001-12-19 2004-10-29 Atherogenics Inc Chalcone derivatives and their use to treat diseases.
FR2839717A1 (en) * 2002-05-15 2003-11-21 Synth E163 Cosmetic compositions containing nitrogen-substituted chalcone derivatives, useful for protection against UV radiation
AU2003229538A1 (en) 2002-05-17 2003-12-02 Lica Pharmaceuticals A/S Aminoalkoxy-functional chalcones
WO2004108094A2 (en) 2003-06-06 2004-12-16 Atherogenics, Inc. Sulfonamide-substituted chalcone derivatives and their use to treat diseases
AU2003273040A1 (en) * 2003-10-17 2005-05-05 Arigen, Inc. Novel phenol derivative and antitrypanosoma preventive/therapeutic agent containing the same as active ingredient
WO2005042467A1 (en) * 2003-10-31 2005-05-12 Lica Pharmaceuticals A/S Quaternary amino-functional chalcones
US20060270614A1 (en) * 2005-05-24 2006-11-30 Sekhar Boddupalli Use of chalcones for the treatment of viral disorders
KR20090029735A (en) * 2006-05-24 2009-03-23 디에스엠 아이피 어셋츠 비.브이. Treating muscular disorders and improving muscular function
WO2009028839A1 (en) * 2007-08-31 2009-03-05 Korea Research Institute Of Chemical Technology Pharmaceutical composition for preventing or treating bone diseases comprising licochalcone a
WO2011097797A1 (en) * 2010-02-10 2011-08-18 Peng Jinlian Polyphenol acrylic acid derivative, preparation and use in preparing medicine thereof
US9126890B2 (en) * 2011-10-20 2015-09-08 International Flavors & Fragrances Inc. Low volatile reactive malodor counteractives and methods of use thereof
AU2012271403C1 (en) * 2011-06-15 2018-02-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nuclear receptor modulators and their use for the treatment and prevention of cancer
CN104523663A (en) * 2014-12-04 2015-04-22 中南民族大学 Application of Loureirin B in preparation of Kv1.3 channel blocker
WO2017103637A1 (en) 2015-12-18 2017-06-22 Blirt S.A. Diphenylpropane compounds and their cytotoxic activity
US10702793B2 (en) 2015-12-22 2020-07-07 Eastman Chemical Company Supersonic treatment of vapor streams for separation and drying of hydrocarbon gases
CN114252548B (en) * 2022-03-02 2022-05-31 江西省药品检验检测研究院 Method for simultaneously detecting multiple components in large seven-li preparation

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5170815A (en) * 1974-12-12 1976-06-18 Mitsubishi Petrochemical Co JOSOZAI
JPS51125736A (en) * 1974-12-03 1976-11-02 Rikagaku Kenkyusho An insecticide for agriculture and gardening
US4321270A (en) * 1981-01-29 1982-03-23 E. R. Squibb & Sons, Inc. Substituted chromans
DE3537207A1 (en) * 1984-10-19 1986-04-30 Biorex Laboratories Ltd., London CHALK DERIVATIVES
JPH04202126A (en) * 1990-11-30 1992-07-22 Terumo Corp Interleukin-i production-inhibiting agent
WO1993017671A1 (en) * 1992-03-06 1993-09-16 Statens Seruminstitut Treatment and prophylaxis of diseases caused by parasites, or bacteria
US5276058A (en) * 1993-06-09 1994-01-04 Nippon Hypox Laboratories Incorporated 3,4-dihydroxychalcone derivatives
JPH06116206A (en) * 1992-10-02 1994-04-26 Morinaga Milk Ind Co Ltd Chalcone derivative and its use
WO1995006628A1 (en) * 1993-09-03 1995-03-09 Statens Seruminstitut Treatment and prophylaxis of diseases caused by parasites or bacteria

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51125736A (en) * 1974-12-03 1976-11-02 Rikagaku Kenkyusho An insecticide for agriculture and gardening
JPS5170815A (en) * 1974-12-12 1976-06-18 Mitsubishi Petrochemical Co JOSOZAI
US4321270A (en) * 1981-01-29 1982-03-23 E. R. Squibb & Sons, Inc. Substituted chromans
DE3537207A1 (en) * 1984-10-19 1986-04-30 Biorex Laboratories Ltd., London CHALK DERIVATIVES
JPH04202126A (en) * 1990-11-30 1992-07-22 Terumo Corp Interleukin-i production-inhibiting agent
WO1993017671A1 (en) * 1992-03-06 1993-09-16 Statens Seruminstitut Treatment and prophylaxis of diseases caused by parasites, or bacteria
JPH06116206A (en) * 1992-10-02 1994-04-26 Morinaga Milk Ind Co Ltd Chalcone derivative and its use
US5276058A (en) * 1993-06-09 1994-01-04 Nippon Hypox Laboratories Incorporated 3,4-dihydroxychalcone derivatives
WO1995006628A1 (en) * 1993-09-03 1995-03-09 Statens Seruminstitut Treatment and prophylaxis of diseases caused by parasites or bacteria

Non-Patent Citations (40)

* Cited by examiner, † Cited by third party
Title
BATT: "2'-substituted chalcone derivtives as inhibitors of interleukin-1 biosynthesis", J. MED. CHEM., vol. 36, no. 10, 1993, pages 1434 - 1442, XP002065671 *
BAUER: "Oligooxa[3n.3]paracyclophane quinhydrones- cation-induced charge-transfer absorptions and structures of the metal complexes", CHEM. BER., vol. 127, no. 10, 1994, pages 1993 - 2008 *
CHALIHA: "Chemical investigation of Citrus reticulata Blanco", INDIAN J. CHEM., vol. 5, no. 6, 1967, pages 239 - 241, XP002065680 *
CHALIHA: "Chemical investigations of Citrus reticulata", INDIAN J. CHEM., vol. 5, no. 6, 1967, pages 239 - 241 *
CHEMICAL ABSTRACTS, vol. 105, no. 15, 1986, Columbus, Ohio, US; abstract no. 126832c, page 21; column 126836; XP002065685 *
CHEMICAL ABSTRACTS, vol. 118, no. 3, 1993, Columbus, Ohio, US; abstract no. 19166k, column 19162; XP002065689 *
CHEMICAL ABSTRACTS, vol. 120, no. 19, 1994, Columbus, Ohio, US; abstract no. 244249a, page 959; column 24453; XP002065691 *
CHEMICAL ABSTRACTS, vol. 120, no. 7, 1994, Columbus, Ohio, US; abstract no. 73402p, page 49; column 73399; XP002065692 *
CHEMICAL ABSTRACTS, vol. 121, no. 9, 1994, Columbus, Ohio, US; abstract no. 103906w, column 103906; XP002065690 *
CHEMICAL ABSTRACTS, vol. 67, no. 25, 1967, Columbus, Ohio, US; abstract no. 114340z, page 10768; column 114331; XP002065687 *
CHEMICAL ABSTRACTS, vol. 70, no. 21, 1969, Columbus, Ohio, US; abstract no. 96339m, page 297; column 96346; XP002065688 *
CHEMICAL ABSTRACTS, vol. 85, no. 9, 1976, Columbus, Ohio, US; abstract no. 57378p, page 102; column 57374; XP002065693 *
CHEMICAL ABSTRACTS, vol. 99, no. 9, 1983, Columbus, Ohio, US; abstract no. 70328f, page 592; column 70318; XP002065686 *
CHEN: "Licochalcone A, a novel antiparasitic agent with potent activity against human pathogenic protozoan species of Leishmania", ANTIMICROB. AGENTS CHEMOTHER., vol. 37, no. 12, December 1993 (1993-12-01), pages 2550 - 2556, XP002065679 *
COLEGATE: "Tepanone, a retrochalcone from Ellipeia cuneifolia", PHYTOCHEMISTRY, vol. 31, no. 6, 1992, pages 2123 - 2126, XP026633439, DOI: doi:10.1016/0031-9422(92)80377-Q *
DATABASE CHEMABS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002065695 *
DATABASE MEDLINE XP002065694 *
DATABASE WPI Week 7631, Derwent World Patents Index; AN 76-58928x, XP002065696 *
DATABASE WPI Week 7651, Derwent World Patents Index; AN 76-95127x, XP002065697 *
DE SHANTANU: "A simple and efficient conversion of chalcones to dihydrochalcones", INDIAN J. CHEM., SECT B, vol. 33b, no. 2, 1994, pages 163 - 165 *
DEVI: "In-vitro effects of natural plant polyphenols on the proliferation of normal and abnormal human lymphocytes and their secretions of interleukin-2", CANCER LETT., vol. 69, no. 3, 1993, pages 191 - 196, XP002065670 *
HAYASHI: "Butein (3,4,2',4'-tetrahydroxychalcone ameliorates experimental glomerular basement membrane antibody-associated glomerulonephritis", EUR. J. PHARMACOL., vol. 316, no. 2-3, 5 December 1996 (1996-12-05), pages 297 - 306, XP002065676 *
HAYASHI: "Butein ameliorates experimental anti-glomoerlar basement membrane (GBM) antibody-associated glomerulonephritis in rats", JPN J. PHARMACOL., vol. 70, no. 1, 1996, pages 55 - 64, XP002065674 *
IWATA: "Antitumor activities of chalcones (II). Photo-isomerization of chalcones and the correllation with their biological activities", BIOL. PHARM. BULL., vol. 20, no. 112, 1997, pages 1266 - 1270, XP002065677 *
KAMIYA: "Effect of sofalcone on adherence, production of vacuolating toxin and induction of interleukin-8 secretion by Helicobacter pylori", J. CLIN. GASTROENTEROL., vol. 25, no. 1sup, 1997, pages s172 - s178, XP002065672 *
LU: "Suppressive effects of safflower yellow on immune functions", CHUNG KUO YAO LI HSUEH PAO, vol. 12, no. 6, November 1991 (1991-11-01), pages 537 - 542 *
MANACKE: "Über die Synthese und das Redoxverhalten einiger Modellsubstanzen für polymere Hydrochinon-Chinon-Redoxsysteme. V", MAKROMOL. CHEM., vol. 108, 1967, pages 198 - 209, XP002065683 *
MASAYUKI: "Accumulation of physical constants of organic constants. Chalcone derivatives for identification of aromatic aldehydes", FUKUSHIMA DAIGAKU KYOIKUGAKUBU RIKA, vol. 32, 1982, pages 39 - 42, XP001027040 *
MAYUNGA: "Antimalarials and other constituents of plants of the genus Uvaria. 9. Three flavonoids from the stem bark of the antimalarial Uvaria dependens", PHYTOCHEMISTRY, vol. 34, no. 3, 1993, pages 853 - 856 *
MEUNIER: "nŸ 512. Recherches en série hétérocyclique. XI. Etude polarographique d'o-hydroxychalcones et de sels de benzopyrylium", BULL. SOC. CHIM. FR., vol. 8, 1967, pages 2872 - 2880, XP002065681 *
NAMGOONG: "Effects of naturally occuring flavonoids on mitogen-induced lymphocyte proliferation and mixed lymphocyte culture", LIFE SCI., vol. 54, no. 5, 1994, pages 313 - 320, XP002065684 *
OGANESYAN: "Study of structure-activity (SA) interrelations in the flavonoid series. I . synthesis of chalcone derivatives and quantitative SA analysis", KHIM. -FARM., vol. 20, no. 6, 1986, pages 696 - 702 *
PATENT ABSTRACTS OF JAPAN vol. 0, no. 0 *
SALLAI: "Relations between the antibacterial activity and structure of some chalcones", ACTA PHARM. HUNG., vol. 46, no. 3, 1976, pages 49 - 56 *
SATO: "Growth inhibitory properties of chalcones to Candida", LETT. APPL. MICROBIOL., vol. 18, no. 1, 1994, pages 53 - 55 *
SCHWARTZ ET AL.: "Comparison of the effects of quercetin with those of other flavonoids on the generation and effector function of cytotoxic T-lymphocytes", IMMUNOPHARMACOLOGY, vol. 7, no. 2, April 1984 (1984-04-01), pages 115 - 126, XP002065678 *
SHOJI: "Antitumor-promoting and antiinflammatory activities of licorice principles and their modified compounds", CAS SYMP. SER., FOOD PHYTOCHEM. CANCER PREVENTION II, vol. 547, 1994, pages 308 - 321, XP002065673 *
SZELL: "Nitrochalcones IX", CAN. J. MED., vol. 47, no. 7, 1969, pages 1254 - 1258, XP001027151, DOI: doi:10.1139/v69-207 *
TSUCHIYA: "Anti-Candida activity of synthetic hydroxychalcones", PHARMAZIE, vol. 49, no. 10, 1994, pages 756 - 758, XP002065682 *
YAO: "Prevention of lens protein-, endotoxin-, and interleukin-1 induced uveitits with chalcone derivatives", INFLAMMOPHARMACOLOGY, vol. 2, no. 4, 1994, pages 401 - 409, XP002065675 *

Also Published As

Publication number Publication date
EP0996432A2 (en) 2000-05-03
WO1999000114A2 (en) 1999-01-07
AU7908098A (en) 1999-01-19

Similar Documents

Publication Publication Date Title
WO1999000114A3 (en) Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones
FI20115753A (en) Pharmaceutical compositions for the treatment of diseases caused by IL-6 production
NO20024772L (en) Percyquinnin, the method of its preparation and its use as a drug
DK0495982T3 (en) Bicyclic pyrimidine derivative, process for its preparation and pharmaceutical composition comprising this as an active ingredient
BR9503386A (en) Dispersible tablet pharmaceutical formulation and process for the manufacture of dispersible tablets containing fluoxetine hydrochloride
CA2183972A1 (en) Oxazolidinone derivatives and pharmaceutical compositions containing them
WO2002100347A3 (en) Prodrugs of gaba analogs, compositions and uses thereof
TW225532B (en)
FR2825925B1 (en) PROCESS FOR PREPARING AN ACTIVE INGREDIENT FROM RICE, ACTIVE INGREDIENT OBTAINED AND SUITABLE COMPOSITIONS
BR0206935A (en) Compound, pharmaceutical formulation, use of a compound, method of treatment and / or prophylaxis of conditions associated with glycogen synthase kinase-3 inhibition, and process for preparing a compound
EP0404283A3 (en) 11-beta-aryl-4-estrene, method for its production and its use as a medicine
WO2001000617A3 (en) Novel piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same, and a process for the preparation of the same
WO2001079174A8 (en) A pyridine-1-oxide derivative, and process for its transformation into pharmaceutically effective compounds
ATE310010T1 (en) 6-0-SUBSTITUTED ERYTHTHROMYCIN COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
DE69717843D1 (en) CIS-3,4-CHROME DERIVATIVES FOR THE PREVENTION OR TREATMENT OF OESTROGEN-RELATED DISEASES OR SYNDROMS
CA2442210A1 (en) Aryl oxime-piperazines useful as ccr5 antagonists
BR9611276A (en) Compound pharmaceutical formulation process for treatment or prophylaxis of diseases or conditions of humans and use of a compound
MXPA03000166A (en) Preparation of phosphatase inhibitors.
AU1192397A (en) Substituted thiazolines and their use for controlling animal pests
BR0214529A (en) therapeutic compounds
DK1123937T3 (en) Substance GM-95, process for its preparation and use thereof
WO2003024996A3 (en) Antibacterial macrocycles
SE9700244D0 (en) Novel antibacterial protein
EE05090B1 (en) Tsipostin compound for use as an antidiabetic drug, pharmaceutical preparation containing it, preparation of the compound and preparation and the micro-organism
DE69718500D1 (en) (-) - ENANTIOMERS OF CIS-3,4-CHROMANE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF OESTROGEN-RELATED DISEASES OR SYNDROMS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE EE ES FI FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE EE ES FI FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 09462125

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1998929241

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1999505229

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998929241

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1998929241

Country of ref document: EP